Novo Sparks a New Fight to Fix MASH

Novo’s Akero buy raises the stakes in MASH as investors await key fibrosis data

14 Nov 2025

Novo Nordisk’s plan to buy Akero Therapeutics for nearly $10bn has startled the metabolic drug world. The focus is MASH, a liver disease linked to obesity and diabetes that seldom makes the news but is growing quickly and draining health budgets.

The prize is efruxifermin, Akero’s experimental drug that aims to curb inflammation and ease fibrosis. Early trials suggested notable reductions in scarring, raising hopes of real disease modification rather than simple symptom control. Such signals must survive larger studies, yet analysts already see the drug as one of the clearer candidates to shift treatment norms.

For Novo, the move edges beyond its booming weight loss franchise. It also signals that silent liver disease is becoming a strategic front. The firm argues that treating MASH earlier could prevent advanced damage that is expensive and often irreversible. Its bet is likely to prod rivals to speed their own programmes and seek partners as the metabolic contest intensifies.

Regulators are moving the goalposts too. Rather than accepting drugs that merely slow decline, they now want evidence that therapies can reverse fibrosis. The higher bar raises costs and risks, but phase 3 success would reset clinical standards and unlock a lucrative market for whoever arrives first.

The deal also reflects a broader shift in industry logic. Drugmakers are moving from managing metabolic warning signs to confronting long term organ injury. That pivot is fuelling interest in new diagnostics, digital tools and more integrated models of care. Investors say the momentum now invites participation from hospitals, insurers and technology firms.

Many see Novo’s bid as a potential turning point. Scientific progress is picking up, capital is flowing and hopes for transformative treatments are growing. Attention will soon return to phase 3 data for efruxifermin and to whether this ambitious purchase can reshape care for a disease that often stays hidden until it is too late.